Wednesday, 25 Apr 2018

You are here

Apremilast Continues to Look Good in Behcet's Disease

The 2018 American Academy of Dermatology (AAD) Annual Meeting features recent findings of a phase III trial of apremilast in active Behçet’s Disease, showing significant reductions in oral ulcers at week 12 for those treated with apremilast 30 mg twice daily.

The RELIEF trial studied 207 patients who were randomized to apremilast 30 mg BID or placebo. The trial’s primary endpoint was the area under the curve (AUC) for the number of oral ulcers at week 12.

The AUC was significantly for apremilast versus placebo (129.5 vs. 222.1; P<0.0001). Significant improvements were also seen with apremilast in multiple secondary endpoints, including oral ulcer pain (P<0.0001), overall disease activity (Behçet’s Syndrome Activity Score: P<0.0001; Behçet’s Disease Current Activity Index: P=0.0335) and quality of life (P=0.0003).

Diarrhea was the most frequent adverse event (41.3 percent with apremilast, 19.4 percent for placebo). Otherwise the safety profile was consistent with the known safety profile of apremilast.

Celgene intends to submit its supplemental New Drug Applications for apremilast in active Behçet’s Disease with oral ulcers in the U.S. in the second half of this year.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Will Aspirin Cotherapy Undermine Celecoxib’s Safety Effects?

The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA). It showed that celecoxib had fewer gastrointestinal events, fewer renal events and less ATPC cardiac events compared to ibuprofen - with an 18% reduction in major CV events and a 32% reduction in all-cause mortaility compared to ibuprofen.

Medicare Drug Prices Jump Ten Times the Inflation Rate

CNN reports that a new congressional analysis of Medicare drug pricing shows the prices of the 20 most commonly prescribed brand-name drugs have risen nearly 10 times the annual rate of inflation in the past five years.

Shoe Inserts Disappoint with Plantar Heel Pain

A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.

Leflunomide May Sensitize the Insulin Receptor and Have an Anti-Glycemic Effect

An animal model study in the Journal of Endocrinololgy reports the potential use of leflunomide in the control of hyperglycemia in male mice. 

2017 Rheumatology Year in Review

This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017.  In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.